Introduction
Rituximab, a chimeric anti-CD20 antibody, dramatically improved the treatment outcome of both indolent and aggressive non-Hodgkin lymphoma (NHL) through its use as a single agent or in combination with chemotherapy (1, 2) . While rituximab ultimately depletes B cells through binding to CD20, its mechanism of action is attributed to a combination of direct apoptosis induction and activation of immune effector mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC) (3) . Despite the success of rituximab, incomplete treatment responses and emergence of resistance represent important limitations (1) . In an attempt to overcome these limitations, a plethora of second generation anti-CD20 antibodies have been introduced into clinical development, most notably ofatumumab and obinutuzumab which have gained regulatory approval in B-cell chronic lymphocytic leukemia (CLL) (4) . CD20 expression is confined to a B-cell subset, restricting the utility of these agents to patients with CLL and B-cell NHL. Therefore, identification of new targets with a broader expression spectrum and potential for antibody mechanisms similar to rituximab could yield novel antibody therapeutics for a wider range of hematologic malignancies.
The cell surface molecule CD38 represents such an opportunity since it is expressed in multiple hematologic malignancies derived from both lymphoid and myeloid lineages, including multiple myeloma (MM), a CD20 negative B-cell malignancy (5) . CD38 is a 45 kDa type II transmembrane glycoprotein that has been described as both a receptor and a multifunctional enzyme involved in the production of nucleotide-metabolites (6) (7) (8) . It has been proposed to associate with cell surface proteins in lipid rafts, regulate CD38 expression is an important prognostic factor in B-CLL that identifies patients with aggressive disease and poor survival (17) (18) (19) . It has been proposed that CD38 plays a role in the proliferation and survival of CLL cells (20) . High CD38 expression has been reported on plasma cells as well as their malignant counterparts, MM cells, leading to its widespread use as a surface marker, combined with CD138, to enumerate malignant myeloma cells in patient bone marrow (5, 21) . Overall, CD38 expression in hematologic malignancies and its correlation with disease progression makes CD38 an attractive target for antibody-based therapeutics. Several anti-human CD38 antibodies differing in their functional properties against various malignant cells and cell lines have been described in the literature (10, (22) (23) (24) (25) (26) (27) . A recently developed antibody, daratumumab, is currently undergoing clinical trials in MM patients and reported to have a manageable safety profile and early signs of efficacy (28) (29) (30) . Another anti-CD38 antibody, MOR202, is being evaluated in a phase 1/2a trial in patients with relapsed/refractory MM (31, 32 
Materials and methods

Cell culture
Ramos, Raji, Daudi, and Namalwa lymphoma cells were obtained from American Type Culture Collection (ATCC). All other cell lines were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). Cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 2 mM glutamine and 1% penicillin-streptomycin (Life Technologies) at 37°C in a humidified 5% CO 2 incubator.
Antibody generation
CD38-binding murine monoclonal antibodies were generated by standard hybridoma technology following immunizations with murine 300-19 cells transfected to express the full-length human CD38 antigen. Antibodies were chimerized (ch) as huIgG1-kappa and humanized (hu) by variable domain resurfacing (33) . Chimeric antibodies chHB7 and chOKT10 were produced based on sequences derived from their respective murine hybridomas (ATCC HB-136, CRL-8022). Ab005 (a surrogate antibody for daratumumab) and huAT13/5 were produced based on published sequences (Genbank:   ADS96869 and ADS96865, corresponding to sequences 17 and 12 from US7829673 for Ab005, CAA03366 and CAA03368 for huAT13/5). IB4 and SUN-4B7 were a gift from 
Apoptosis induction
Binding assay
Antibodies were incubated with 5 x 10 4 cells/assay in RPMI-1640 with 2% normal goat serum and 0.1% sodium azide (both Sigma-Aldrich) for 3 hours on ice followed by incubation with FITC-conjugated goat-anti-mouse or anti-human IgG antibody (Jackson ImmunoResearch) for 1 hour on ice. Samples were analyzed on a FACSCalibur flow cytometer as above. Sigmoidal dose-response curves were generated and EC 50 values calculated using GraphPad Prism (GraphPad Software, San Diego).
Expression analysis
Cells were incubated in PBS with 0.1% sodium azide and 0.5% BSA (Sigma-Aldrich) at Monocyte-derived macrophages were prepared by isolating monocytes from peripheral blood using CD14+ beads and culturing them in the presence of 50 ng/mL hGM-CSF 
Enzymatic activity assay
A recombinant soluble human CD38-Fc fusion protein was produced, and enzymatic activity assays carried out as described in the Supplementary Data section (36) .
3D structure analysis
Crystals of the non-glycosylated soluble human CD38 antigen (extracellular domain R45-I300) and the SAR650984 Fab fragment were obtained and analyzed as described 
Results
Antibody generation and selection
We generated a large panel of murine monoclonal antibodies that specifically bound to human CD38 (huCD38). In order to identify antibodies with intrinsic anti-cancer cell activity, antibodies were screened for their ability to induce apoptosis in lymphoma cells in the absence of any cross-linking agents. One of the antibodies identified had notably strong pro-apoptotic activity, inducing 35% Annexin V-positive Daudi cells compared to 6% Annexin V-positive cells in the absence of antibody (Fig. 1A) . In contrast, other anti-CD38 antibodies generated in our screen, such as clones 7 and 23, did not induce a significant increase in Annexin V staining of cells. Previously generated anti-CD38 antibodies huAT13/5, chOKT10, IB4, and SUN-4B7 also resulted at best in a minor (14% or less) increase in the percentage of Annexin V-positive Daudi cells. This murine lead clone was therefore chosen for further analysis based on its unique pro-apoptotic activity and humanized by variable domain resurfacing. The chimeric and humanized versions of the lead clone retained specific, high-affinity binding to human CD38 with an apparent Kd of 0.2 nM (Fig. 1B) . Its humanized IgG1 version was designated as SAR650984.
Functional activity of the humanized anti-CD38 antibody SAR650984
Superior pro-apoptotic activity by SAR650984 over rituximab in the absence of crosslinking agents was seen in Raji, Daudi and Ramos lymphoma cells, which express CD20 and CD38 at similar levels ( Fig. 2A and B) . In addition SAR650984 induced Fig. 2C and D) . In addition, SAR650984 mediated antibody-dependent cell-mediated phagocytosis (ADCP) with human macrophages against Ramos cells to a similar extent as rituximab at 10 μg/mL (Fig. 2E) .
SAR650984 activity against a panel of diverse cell lines
CD38 is expressed on a wider range of malignant cell types than CD20, providing the potential for an expanded utility of a therapeutic anti-CD38 antibody (5). We therefore characterized a larger panel of cell lines for their CD38 expression level and SAR650984 in vitro activity. CD38 levels were determined by quantitative flow cytometry and ranged from 790,000 to 59,000 antibodies bound per cell (ABC) in the 15 cell lines tested representing B-cell NHL, MM, B-CLL, T-cell acute lymphoblastic leukemia (ALL) and B-cell ALL (Fig. 3A) . (Fig. 3B) .
Research. Figure 3D ). SAR650984 mediated ADCP with 60% phagocytosed Ramos cells, compared to 25% in untreated samples, with an EC 50 value of 5 ng/mL (Fig. 3E) . While ADCC activity was seen against all CD38+ cell lines tested regardless of CD38 expression level, apoptosis induction and CDC activity was most often seen against cell lines with the highest CD38 levels (Fig. 3A) .
Binding of SAR650984 to normal human peripheral blood cells was assessed by flow cytometry. SAR650984 specifically bound to monocytes and T cells ( Supplementary   Fig. S1A and B) with the same affinity seen on tumor cells. We observed low levels of CD38 expression in normal human blood cells with 3,000 to 14,000 ABC, much lower than levels of CD20 expression on B cells (Supplementary Fig. S1C ). SAR650984 treatment did not deplete peripheral blood cells cultured in vitro (Supplementary Fig.   S1D ), whereas rituximab resulted in B-cell depletion and alemtuzumab in both B-and Tcell depletion.
Apoptosis induction in primary MM patient cells
The ability of SAR650984 to induce apoptosis without the addition of external crosslinking agent was also tested in primary cells isolated from bone marrow aspirates of 7 MM patients. SAR650984 noticeably increased the percentages of AnnexinV positive cells over background levels in all MM samples tested with a mean increase of 25% AnnexinV-positive cells (Fig. 3F) . 
Enzymatic activity
Inhibition of the adenosine diphosphate (ADP) ribosyl-cyclase enzymatic activity of human CD38 by SAR650984 and other anti-CD38 antibodies was evaluated in vitro.
SAR650984 inhibited the enzymatic function of 5 nM recombinant CD38 almost completely at concentrations of 200 and 20 nM with partial inhibition at 2 nM concentration ( Figure 4A) . A human IgG1 isotype control antibody had no measurable inhibitory effect in these experiments. Other anti-CD38 antibodies tested, Ab005 (a surrogate antibody for daratumumab), chHB7, huAT13/5 and chOKT10, resulted in much lower or no inhibitory effect (Fig. 4B ).
3D structure of the huCD38/SAR650984-Fab complex
Mapping of the epitope and identification of the paratope was achieved by determining the crystal structure of soluble human CD38 (huCD38) in complex with the Fab fragment from SAR650984 at 1.53 Å resolution (PDB ID code: 4CMH, Fig. 4C ).
Residues that are part of the huCD38 epitope bound by SAR650984-Fab are highlighted in Figure 4D and notably include a continuous segment from Met110 to Cys119. Mutations introduced to silence the four glycosylation sites of CD38 are not part of the huCD38/SAR650984-Fab interface.
A close-up view of the epitope shows that the interface between huCD38 and SAR650984-Fab involves only part of the residues in the CDR loops (Fig. 4E) . Heavy chain CDR Loop H3 protrudes out of the structure of SAR650984-Fab and is particularly critical for complex stabilization while Loop H1, H2, L1, L2 and L3 are located at the periphery of the interface. Four salt-bridges form the interactions between H1 and H2 with Arg194 and Lys111 of huCD38 ( Supplementary Fig. S2 ). Binding of SAR650984- Fab induces local conformational changes in the huCD38 structure. The most significant conformational change affects the segment Gln115-Thr116-Val117 of huCD38 that is shifted by ~2.5Å towards the light chain, creating enough space to accommodate the H3 loop of SAR650984-Fab (Fig. 4E) . However, the configuration of key residues involved in the ADP-ribosyl cyclase activity of CD38 is maintained and the catalytic site remains accessible (Fig. 4F) , suggesting SAR650984 is likely an allosteric antagonist.
In vivo activity against lymphoma and leukemia models
We evaluated the in vivo efficacy of SAR650984 in comparison to established lymphoma treatments such as rituximab and chemotherapy. SAR650984 showed similar anti-tumor activity as rituximab in a disseminated xenograft model established from CD20+ CD38+ Daudi lymphoma cells (Fig. 5A) . Treatment with 40 mg/kg SAR650984 or rituximab twice weekly for 3 weeks markedly increased survival with a median increase in lifespan (%ILS) of 68% for SAR650984 and 52% for rituximab as compared to untreated control animals. SAR650984 was also highly efficacious in a disseminated NALM-6 B-ALL xenograft model, with a median %ILS of >200% at doses of ≥ 2.5 mg/kg (Fig. 5B) analyzed for the levels of cleaved caspase 7, a marker for apoptotic pathway activation, in comparison to untreated tumors. SAR650984 induced a 64% or 169% increase in cleaved caspase 7 levels after 14 or 24 hours, respectively (Fig. 5D ).
In vivo activity against multiple myeloma models
Next, we examined the utility of SAR650984 in subcutaneous xenograft models derived from CD20-CD38+ MM cell lines Molp-8 and NCI-H929 in comparison with bortezomib, an established MM treatment. In a study with palpable Molp-8 tumors SAR650984 was well tolerated and active at 40, 25, and 15 mg/kg administered twice weekly for three weeks with T/C values of 8%, 10%, and 12%, respectively (Fig. 6A) . Bortezomib treatment at 0.7 or 0.4 mg/kg administered twice weekly for two weeks was inactive, while higher doses of 1.2 or 1.9 mg/kg were toxic.
Similarly, in a study with established NCI-H929 tumors, SAR650984 treatment was well tolerated and highly active at 40, 20, and 10 mg/kg x6 with 10/10 tumor-free survivors and at 5 mg/kg x6 with 9/10 tumor-free survivors at study end (Fig. 6B) . Bortezomib administered twice weekly for two weeks was highly active at 0.6 mg/kg (T/C 7.8%; 4/10 tumor-free survivors), and at 1 mg/kg (10/10 tumor-free survivors). A higher bortezomib dose of 1.6 mg/kg was toxic, while a dose of 0.4 mg/kg was inactive.
Discussion
The introduction of therapeutic monoclonal anti-CD20 antibodies, such as rituximab, ofatumumab and very recently obinutuzumab, are improving outcomes for patients with 
B-cell malignancies, although unmet medical need remains. It would be desirable to develop antibody therapeutics for other hematologic diseases, in particular MM, that could also combine high efficacy with low systemic toxicity. Our goal was to build upon the success story of CD20 antibody therapy by developing a novel multi-functional antibody directed against a different target with expanded utility in a range of hematologic malignancies. Here, we describe the generation and characterization of SAR650984, a CD38-targeting antibody with a unique combination of anti-tumor activities.
The ability of SAR650984 to induce apoptosis in vitro was superior to rituximab in B-cell lymphoma cell lines with similar CD38 and CD20 expression, with potent activity even in the absence of cross-linking agents. This type of enhanced pro-apoptotic activity has been described for type II anti-CD20 antibodies such as tositumumab or obinutuzumab 
xenograft tumors, while bortezomib, an agent commonly used in MM treatment, was only active against NCI-H929 tumors.
Several anti-CD38 antibodies with various functional properties have been identified previously. While some of these can mediate in vitro killing of CD38+ cell lines via ADCC and/or CDC effector function, their direct impact on cell proliferation or apoptosis remains unclear (10, (22) (23) (24) . For example, the agonistic antibody IB4 was reported to prevent apoptosis or induce proliferation in some contexts (10, 38) , and induce apoptosis in another (9) . The more recently developed antibody daratumumab has been shown to mediate ADCC as well as ADCP but to induce apoptosis only in the presence of stromal cells or cross-linking agents (28, 39) . It was selected based on its CDC activity, which may be linked to its unique epitope. Another recent addition, MOR202, primarily possesses ADCC activity with CDC and ADCP also being observed with no reported intrinsic pro-apoptotic activity (31, 32) .
Analysis of the 3D structure of SAR650984-Fab with human CD38 revealed that SAR650984 binds to a discontinuous epitope which includes amino acids located opposite to the catalytic site of CD38. While significant conformational changes are observed in CD38 upon binding by SAR650984, the overall configuration of key residues involved in the CD38 enzymatic activity and access to the catalytic site appear conserved (40) (41) (42) . Nevertheless, SAR650984 strongly inhibits CD38 enzymatic activity suggesting that SAR650984 is an allosteric rather than an orthosteric antagonist of CD38. This is different from HB7, an antibody that does not compete with SAR650984
( Supplementary Fig. S3 ), binds at a different location in the C-terminal portion of the CD38 extracellular domain (Supplementary Fig. S4 ) and does not inhibit CD38 enzymatic activity (Fig. 4B) . The SAR650984 binding mode appears unique as other anti-CD38 antibodies tested here or described elsewhere show no or much less potent inhibition of the enzymatic activity.
CD38 enzymatic activities produce nucleotide-metabolites including cADPR, which induce Ca2+ mobilization and signaling (7, 8, 43) . However, the physiological role of CD38 is still unknown, as functional studies have mainly used cell lines ectopically overexpressing CD38 and anti-CD38 antibodies, which are non-physiological ligands (44, 45) . Therefore, the exact interplay between enzymatic activity, receptor function and consequences on signaling pathways and cellular response remains to be further documented. As a consequence, the physiological impact of SAR650984 inhibition of CD38 enzymatic activity remains to be deciphered and how the functional differences 
